product summary
Loading...
company name :
Novus Biologicals
other brands :
IMGENEX
product type :
antibody
product name :
GEMIN8 Antibody (OTI1E5)
catalog :
NBP2-45832
quantity :
0.1 ml
price :
479 USD
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
OTI1E5
reactivity :
human
application :
western blot, immunohistochemistry, immunohistochemistry - paraffin section
more info or order :
product information
master code :
NBP2-45832
SKU :
NBP2-45832
product name :
GEMIN8 Antibody (OTI1E5)
unit size :
0.1 ml
description :
The GEMIN8 Antibody (OTI1E5) from Novus is a mouse monoclonal antibody to GEMIN8. This antibody reacts with human. The GEMIN8 Antibody (OTI1E5) has been validated for the following applications: Immunohistochemistry-Paraffin,Immunohistochemistry,Western Blot.
target :
GEMIN8
category :
Primary Antibodies
buffer :
PBS (pH 7.3), 1.0% BSA and 50% Glycerol
clonality :
Monoclonal
clone :
OTI1E5
concentration :
1 mg/ml
conjugate :
Unconjugated
host :
Mouse
immunogen :
Full length human recombinant protein of human GEMIN8 (NP_060326) produced in E.coli.
isotype :
IgG1
purity :
Immunogen affinity purified
species :
Human
theoretical molecular weight :
28.5 kDa
gene symbol :
GEMIN8
applications :
Immunohistochemistry-Paraffin,Immunohistochemistry,Western Blot
USD :
479 USD
alt names :
FAM51A1, FLJ43072, gem (nuclear organelle) associated protein 8, Gemin-8, member A1, Protein FAM51A1
storage :
Store at -20C. Avoid freeze-thaw cycles.
more info or order :
company information

Novus Biologicals
10771 E Easter Ave
Centennial, CO 80112
Centennial, CO 80112
novus@novusbio.com
https://www.novusbio.com3037301950
headquarters: USA
Novus Biologicals licenses, manufactures, and markets antibodies to over 20,000 unique targets to support a wide array of research areas. Novus is built on honesty, collaboration and strong relationships and continues to provide quality tools that accelerate research. Every product is backed by our 100% guarantee.
related products
browse more products
questions and comments